A randomized open-label trial of on-demand rabeprazole vs ranitidine for patients with non-erosive reflux disease

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 18, Issue 19

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

All Articles published online

Item

Count

PDF

464

HTML

3710

Figures (1-1)

212

Tables (1-2)

189

Sum=4575

May 21, 2012 (publication date) through Dec 11, 2024

Times Cited of This Article

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Brief Article

World J Gastroenterol. May 21, 2012; 18(19): 2390-2395
Published online May 21, 2012. doi: 10.3748/wjg.v18.i19.2390

Full Size Figure Download Figure

Figure 1 Mean quality of life scores at baseline and immediately after treatment (n = 25 at baseline). Group A, rabeprazole; Group B, ranitidine.

Citation: Kobeissy AA, Hashash JG, Jamali FR, Skoury AM, Haddad R, El-Samad S, Ladki R, Aswad R, Soweid AM. A randomized open-label trial of on-demand rabeprazole vs ranitidine for patients with non-erosive reflux disease. World J Gastroenterol 2012; 18(19): 2390-2395
URL: https://www.wjgnet.com/1007-9327/full/v18/i19/2390.htm
DOI: https://dx.doi.org/10.3748/wjg.v18.i19.2390